Performance measurements from the first phase of our ongoing two-part validation study for the Prostate Core Mitomic Test™ for prostate cancer yield positive results.
Our tissue-based Mitomic Prostate Core Test™ receives positive results from an independent post-market study conducted by the prestigious uro-oncology trials management organization, CUSP Group.
The study will evaluate the Company’s novel mitochondrial DNA-based test for accurately identifying prostate cancer in blood samples from men with elevated PSA levels that are at risk for prostate cancer.
MDNA Life Sciences acquires Mitomic Technology and product pipeline.
Sophisticated new prostate cancer tests are coming to market that might supplement the unreliable P.S.A. test, potentially saving tens of thousands of men each year from unnecessary biopsies, operations and radiation treatments.
Read the full article on the New York Times.